UniQure un­veils mixed Hunt­ing­ton's gene ther­a­py da­ta, shares tank

UniQure shared up­dat­ed da­ta from a Phase I/II study that showed a clin­i­cal ben­e­fit in a small group of pa­tients with Hunt­ing­ton’s dis­ease who re­ceived its gene ther­a­py, but con­flict­ing da­ta about the mu­tant Hunt­ingtin pro­tein sent shares $QURE down by about 40% on Wednes­day morn­ing.

The Dutch biotech on Wednes­day re­vealed new da­ta from the place­bo-con­trolled Phase I/II study with 26 pa­tients. Six­teen pa­tients were giv­en a low or high dose of AMT-130, with 10 pa­tients in the con­trol group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER